NEW YORK, July 7, 2017 /PRNewswire/ --
If you want a Stock Review on MNK, PTHN, ZTS or INNL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has selected these four Generic Drugs companies for scanning: Mallinckrodt PLC (NYSE: MNK), Patheon N.V. (NYSE: PTHN), Zoetis Inc. (NYSE: ZTS), and Innocoll Holdings PLC (NASDAQ: INNL). Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals. Generic drugs are produced and distributed without patent protection, and industry operators are not significantly engaged in the research and development of new drugs. Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
http://dailystocktracker.com/register/
Mallinckrodt
Shares in Chesterfield, the UK-based Mallinckrodt PLC saw a drop of 4.87%, ending Thursday's trading session at $43.02. The stock recorded a trading volume of 2.59 million shares, which was higher than its three months average volume of 2.14 million shares. The Company's shares have gained 7.34% in the last one month. The stock is trading 1.74% below its 50-day moving average. Moreover, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, Middle-East, Africa, and internationally, have a Relative Strength Index (RSI) of 44.85.
On June 16th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $52 per share.
On June 29th, 2017, Mallinckrodt announced that it will report Q2 FY17 earnings results for the period of April 01st, 2017 to June 30th, 2017 on August 08th, 2017. A conference call for investors will begin at 8:30 a.m. ET on that same day. The call can be accessed via the Company's website. Visit us today and access your complete report on MNK for free at:
http://dailystocktracker.com/registration/?symbol=MNK
Patheon
Amsterdam, the Netherlands-based Patheon N.V.'s stock declined 0.03%, closing the day at $34.86 with a total trading volume of 283,436 shares. The Company's shares have advanced 0.32% in the past month, 32.90% in the previous three months, and 21.42% since the start of this year. The stock is trading 7.39% and 18.93% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Patheon, which provides outsourced pharmaceutical development and manufacturing services, have an RSI of 78.88.
On June 09th, 2017, research firm Leerink Partners downgraded the Company's stock rating from 'Outperform' to 'Market Perform'.
On June 29th, 2017, Patheon announced that it expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities. Key areas include the Company's recently acquired site in Florence, South Carolina; its low-solubility center of excellence in Bend, Oregon; its new, commercial sterile product manufacturing facility in Monza, Italy; and its Greenville, NC site. The complimentary research report on PTHN can be accessed at:
http://dailystocktracker.com/registration/?symbol=PTHN
Zoetis
On Thursday, shares in Parsippany, New Jersey headquartered Zoetis Inc. recorded a trading volume of 2.32 million shares. The stock ended the day 1.22% lower at $61.79. The Company's shares have advanced 17.32% in the previous three months and 15.43% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.44% and 13.25%, respectively. Furthermore, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have an RSI of 45.80.
On June 16th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $75 per share.
On June 30th, 2017, Zoetis announced that it will host a webcast and conference call at 8:30 a.m. ET on August 08th, 2017. CEO Juan Ramón Alaix and Executive Vice President and CFO Glenn David will review Q2 2017 financial results and respond to questions from financial analysts during the call. The live webcast may be accessed via the Company's website. Register for free on DailyStockTracker.com and download the research report on ZTS at:
http://dailystocktracker.com/registration/?symbol=ZTS
Innocoll
Athlone, Ireland headquartered Innocoll Holdings PLC's stock finished yesterday's session flat at $2.27 with a total trading volume of 13,661 shares. The Company's shares have advanced 4.61% in the last one month, 3.65% in the previous three months, and 228.99% on an YTD basis. The stock is trading above its 50-day moving average by 4.39%. Additionally, shares of Innocoll, which manufactures and sells collagen-based pharmaceutical products and devices in Europe, Middle-East, Asia, and the US, have an RSI of 53.85. Get free access to your research report on INNL at:
http://dailystocktracker.com/registration/?symbol=INNL
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
If you want a Stock Review on MNK, PTHN, ZTS or INNL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has selected these four Generic Drugs companies for scanning: Mallinckrodt PLC (NYSE: MNK), Patheon N.V. (NYSE: PTHN), Zoetis Inc. (NYSE: ZTS), and Innocoll Holdings PLC (NASDAQ: INNL). Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals. Generic drugs are produced and distributed without patent protection, and industry operators are not significantly engaged in the research and development of new drugs. Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
Advertisement
http://dailystocktracker.com/register/
Mallinckrodt
Shares in Chesterfield, the UK-based Mallinckrodt PLC saw a drop of 4.87%, ending Thursday's trading session at $43.02. The stock recorded a trading volume of 2.59 million shares, which was higher than its three months average volume of 2.14 million shares. The Company's shares have gained 7.34% in the last one month. The stock is trading 1.74% below its 50-day moving average. Moreover, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, Middle-East, Africa, and internationally, have a Relative Strength Index (RSI) of 44.85.
On June 16th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $52 per share.
On June 29th, 2017, Mallinckrodt announced that it will report Q2 FY17 earnings results for the period of April 01st, 2017 to June 30th, 2017 on August 08th, 2017. A conference call for investors will begin at 8:30 a.m. ET on that same day. The call can be accessed via the Company's website. Visit us today and access your complete report on MNK for free at:
http://dailystocktracker.com/registration/?symbol=MNK
Patheon
Amsterdam, the Netherlands-based Patheon N.V.'s stock declined 0.03%, closing the day at $34.86 with a total trading volume of 283,436 shares. The Company's shares have advanced 0.32% in the past month, 32.90% in the previous three months, and 21.42% since the start of this year. The stock is trading 7.39% and 18.93% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Patheon, which provides outsourced pharmaceutical development and manufacturing services, have an RSI of 78.88.
On June 09th, 2017, research firm Leerink Partners downgraded the Company's stock rating from 'Outperform' to 'Market Perform'.
On June 29th, 2017, Patheon announced that it expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities. Key areas include the Company's recently acquired site in Florence, South Carolina; its low-solubility center of excellence in Bend, Oregon; its new, commercial sterile product manufacturing facility in Monza, Italy; and its Greenville, NC site. The complimentary research report on PTHN can be accessed at:
http://dailystocktracker.com/registration/?symbol=PTHN
Zoetis
On Thursday, shares in Parsippany, New Jersey headquartered Zoetis Inc. recorded a trading volume of 2.32 million shares. The stock ended the day 1.22% lower at $61.79. The Company's shares have advanced 17.32% in the previous three months and 15.43% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.44% and 13.25%, respectively. Furthermore, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have an RSI of 45.80.
On June 16th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $75 per share.
On June 30th, 2017, Zoetis announced that it will host a webcast and conference call at 8:30 a.m. ET on August 08th, 2017. CEO Juan Ramón Alaix and Executive Vice President and CFO Glenn David will review Q2 2017 financial results and respond to questions from financial analysts during the call. The live webcast may be accessed via the Company's website. Register for free on DailyStockTracker.com and download the research report on ZTS at:
http://dailystocktracker.com/registration/?symbol=ZTS
Innocoll
Athlone, Ireland headquartered Innocoll Holdings PLC's stock finished yesterday's session flat at $2.27 with a total trading volume of 13,661 shares. The Company's shares have advanced 4.61% in the last one month, 3.65% in the previous three months, and 228.99% on an YTD basis. The stock is trading above its 50-day moving average by 4.39%. Additionally, shares of Innocoll, which manufactures and sells collagen-based pharmaceutical products and devices in Europe, Middle-East, Asia, and the US, have an RSI of 53.85. Get free access to your research report on INNL at:
http://dailystocktracker.com/registration/?symbol=INNL
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
